AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01168323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online spaced education
Description: Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
Study NCT01559636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bivalent oral polio vaccine
Description: vaccine given during immunization campaigns
Study NCT02482376 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy ( SBRT)
Description: Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
Study NCT04232319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality.
Study NCT02350517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Nedaplatin+Endostar
Description: Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
Study NCT03106571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: Tablets twice daily
Study NCT03106571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-4 tablets twice daily
Study NCT03106571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: intravenous methamphetamine
Study NCT03106571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: intravenous methamphetamine
Study NCT01074775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gut infection challenge with M bovis
Description: Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
Study NCT02333461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study NCT02333461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study NCT02333461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study NCT02333461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study NCT02333461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apricot/Nectarine
Description: Participants were randomly assigned to receive one of four botanical interventions or placebo.
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A dose as CJ-15314
Description: A dose as CJ-15314, 1 capsule
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B dose as CJ-15314
Description: B dose as CJ-15314, 1 capsule
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C dose as CJ-15314
Description: C dose as CJ-15314, 1 capsule
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D dose as CJ-15314
Description: D dose as CJ-15314, 2 capsules
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E dose as CJ-15314
Description: E dose as CJ-15314, 1 capsule
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F dose as CJ-15314
Description: F dose as CJ-15314, 2 capsules
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 capsule
Study NCT04297865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 2 capsules
Study NCT03803306 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vedic Medical Astrology
Description: Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
Study NCT03803306 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo vedic medical astrology (PMA)
Description: Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
Study NCT04978883 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02848131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Dasatinib
Description: Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
Study NCT02848131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Quercetin
Description: Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OBE2109
Description: OBE2109 100mg tablets for oral administration once daily
Study NCT03763032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: The patient navigator will provide educational materials, assessments, and counseling to the patients
Study NCT03159416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study NCT01983475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Study NCT01983475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (identical Denosumab volume of normal saline)
Description: The placebo group will receive the identical volume of normal saline at parallel time points.
Study NCT04056416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedBIKE
Description: A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
Study NCT03607214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal spray~Film Sequence
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study NCT03070951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study NCT01122641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg bid
Study NCT01122641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets
Study NCT03919396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-O orthokeratology lenses
Description: Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material.
Study NCT01952132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762
Study NCT01952132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03796728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT™ with Lidocaine
Description: Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
Study NCT03667482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
Study NCT03667482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
Study NCT02262585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 tablet
Study NCT02262585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 capsule
Study NCT03284463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Study NCT03284463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Study NCT01791244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Study NCT01791244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif®
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oscillometry
Description: assessment of peripheral airway resistance using oscillometry
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout testing
Description: assessment of ventilation heterogeneity using multiple breath washout testing
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: assessment of lung function using spirometry
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: assessment of lung function using body plethysmography
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fractional exhaled nitric oxide
Description: assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transfer factor
Description: assessment of gas transfer using single breath transfer factor for carbon monoxide
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: health status
Description: assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
Study NCT04166812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: induced sputum
Description: various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
Study NCT02341560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection - 1.5 mg
Study NCT02341560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection - 3.0 mg
Study NCT02341560 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection Procedure
Description: Sham Procedure
Study NCT01368588 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo RT using IMRT or 3D-CRT
Study NCT01368588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiotherapy (WPRT)
Description: Undergo whole-pelvic radiotherapy (WPRT)
Study NCT02647099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study NCT02647099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02145143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Study NCT02145143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serial 124I PET/CT
Study NCT02145143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyrotropin alpha
Study NCT04148807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Walking with Gait Retraining
Description: A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
Study NCT04148807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Walking Program
Description: A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
Study NCT03402542 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy
Study NCT01009541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: 82.5 mg controlled release tablet administered once daily for three days.
Study NCT01009541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: 165 mg controlled release tablet administered once daily for three days.
Study NCT01009541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: 330 mg controlled release tablet administered once daily for three days.
Study NCT01009541 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 150 mg
Description: 150 mg immediate release capsules administered every 12 hours for three days
Study NCT04479085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing intervention
Description: It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets.
Study NCT04494256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.
Study NCT04494256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT03259230 — intervention group
Intervention type: OTHER
Intervention: Blood Draws
Study NCT03259230 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Study NCT00113841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
Study NCT00113841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioperine
Description: 5 mg (Tablets) orally twice daily
Study NCT01476670 — intervention group
Intervention type: OTHER
Intervention: Monitoring
Description: Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
Study NCT02987231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap
Study NCT02987231 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CAF
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap
Study NCT02987231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES
Description: Local electric stimulation for 120 seconds, once a day for a week
Study NCT02987231 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
Study NCT01651481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102
Study NCT01651481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair and Xyzal
Study NCT02253225 — intervention group
Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
Study NCT01110824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril and carvedilol
Description: Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
Study NCT00377520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 900 mg/m2, intravenous (IV), every 21 days, until disease progression
Study NCT01476722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist multipurpose disinfecting solution
Description: FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
Study NCT06045312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Comparison of the effectiveness of peer or adult education to adolescents with asthma
Study NCT01155713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT02528084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga
Description: patients watch and follow an online yoga video.
Study NCT02528084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard exercises
Description: patients watch and follow an online standard exercises video.
Study NCT02644486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dosage Sevelamer Carbonate + Irbesartan
Description: Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
Study NCT02644486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dosage Sevelamer Carbonate + Irbesartan
Description: Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
Study NCT02644486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan 300mg/d
Study NCT03901417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore (Non-ablative Fractional Laser)
Description: In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
Study NCT03901417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)
Description: In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
Study NCT01798693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)